New treatment strategies for Waldenström macroglobulinemia

Clin Adv Hematol Oncol. 2022 Aug;20(8):506-515.


The development of high-throughput technologies has allowed us to characterize the molecular landscape of hematologic neoplasms and identify somatic mutations. As a result, we can now use these technologies to screen for and diagnose neoplastic disease, model risk factors for progression, make treatment decisions, track response to treatment, and design clinical trials. Waldenström macroglobulinemia (WM), which is a lymphoplasmacytic lymphoma, serves as a good example of how genomic data collected at the bench can be applied at the bedside. MYD88 L265P and CXCR4 nonsense and frameshift mutations are the most common recurrent variants observed in patients who have WM, with detection rates of 90% and 40%, respectively. Knowing about these mutations has made it possible to develop agents that target the underlying signaling pathways. In this review, we describe the various treatment strategies for WM and detail the genotype of the malignant WM cell.

Publication types

  • Review

MeSH terms

  • Humans
  • Lymphoma, B-Cell* / genetics
  • Mutation
  • Myeloid Differentiation Factor 88 / genetics
  • Myeloid Differentiation Factor 88 / metabolism
  • Myeloid Differentiation Factor 88 / therapeutic use
  • Signal Transduction
  • Waldenstrom Macroglobulinemia* / diagnosis
  • Waldenstrom Macroglobulinemia* / drug therapy
  • Waldenstrom Macroglobulinemia* / genetics


  • Myeloid Differentiation Factor 88